Berzosertib
Advanced solid tumors (ovarian, NSCLC, etc.) with chemo/radiation sensitization
- CAS No.
- 1232416-25-9
- Indication Class
- Oncology / Hematology
- Patent Expiry
- To be assessed
- Therapeutic Area
- Oncology / Targeted Therapy
- Target / Mechanism
- ATR
- Labeled Purity
- 98%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- Confirm per inquiry
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
An ATR inhibitor targeting the DNA-damage-repair pathway, a hot combination strategy with chemo-radiotherapy and PARP inhibitors, strong pipeline extensibility.
Oncology / Targeted Therapy · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Product Description
Berzosertib is an investigational small-molecule drug that selectively inhibits the ATR kinase, a key protein in the DNA damage response pathway. Clinical trials have evaluated its potential, often in combination with chemotherapy or other targeted agents, for treating various advanced solid tumors including ovarian neoplasms, non-small cell lung cancer, and head and neck cancers.
Supply source: Unibest · Berzosertib, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.